Asklepios BioPharmaceutical, Inc. And Bayer Healthcare, LLC Announce Collaboration On Gene Therapy For The Treatment Of Hemophilia
10/19/2005 5:10:00 PM
BERKELEY, Calif. & CHAPEL HILL, N.C.--(BUSINESS WIRE)--May 18, 2005--Bayer HealthCare, LLC, Biological Products Division (Bayer BP), and Asklepios Biopharmaceutical Inc. (AskBio), a private development-stage biotechnology company, announced today they have entered into an early-stage research and collaboration agreement to evaluate gene therapy for the treatment of hemophilia B. Pending positive results of a feasibility study, this collaboration could lead to a joint development and commercialization agreement between Bayer BP and AskBio for the novel gene therapy treatment for hemophilia B.
"We are looking forward to working closely with one of the world's most respected and innovative health care companies. Bayer HealthCare has a long-standing and proactive commitment to providing innovative and life-saving treatment. This important collaboration facilitates the first steps toward a combined platform of expertise and resources jointly focused on advancing care for the global hemophilia community," said Sheila Mikhail, CEO of AskBio.
comments powered by